<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896350</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000637640</org_study_id>
    <secondary_id>SCCC-02308</secondary_id>
    <nct_id>NCT00896350</nct_id>
  </id_info>
  <brief_title>Functional MRI in Finding Hypoxia in Patients Undergoing Chemotherapy and Radiation Therapy for Stage III or Stage IV Head and Neck Cancer</brief_title>
  <official_title>Predicting Treatment Response Based on Hypoxia in Head and Neck Cancers Using Non-Invasive Oxygen Sensitive MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Simmons Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as functional MRI, may help measure oxygen levels in
      tumor cells and may help in planning cancer treatment.

      PURPOSE: This phase I trial is studying functional MRI to see how well it works in finding
      hypoxia in patients undergoing chemotherapy and radiation therapy for stage III or stage IV
      head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the undertaken oxygen sensitive MRI for the detection of hypoxia in patients
           with Stage III-IV head and neck cancer.

        -  Correlate MRI parameters with histology, gene expression, and plasma osteopontin.

        -  Correlate tumor hypoxia measurements with patient prognosis and treatment response.

      OUTLINE:

        -  Pre-therapy MRI: Patients undergo blood oxygen level dependant (BOLD) contrast MRI on
           room air breathing over 2 minutes and with oxygen gas over 15 minutes. Patients also
           undergo MR-spectroscopy over 15 minutes to measure choline and lactate markers, and
           dynamic contrast MRI with gadolinium contrast over 8 minutes.

        -  Chemoradiotherapy: Patients receive platinum based chemotherapy every two weeks.
           Patients also undergo radiation therapy for 6 weeks.

        -  Post-radiation MRI: Patients undergo MRI as before chemoradiotherapy. Blood and tumor
           samples are collected at baseline for biomarker analysis associated with tumor
           progression or response.

      After completion of study, patients are followed every 3 months for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI signal sensitivity to oxygen breathing and delayed contrast-enhancement (DCE)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Association between tumor shrinkage and blood oxygen level dependant (BOLD) MRI response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of BOLD MRI response with oxygen breathing and DCE</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of BOLD MRI parameters with histological markers and therapeutic outcomes</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tissue oxygen measurement</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood-oxygen-level-dependent functional magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dynamic contrast-enhanced magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance spectroscopic imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed squamous cell carcinoma of the head and neck

               -  Stage III or IV disease

          -  Measurable disease

          -  Scheduled to undergo standard treatment including radiation therapy and chemotherapy

          -  Participation on study # 092004-010 for tissue procurement

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Serum creatinine ≤ 1.5 OR creatinine clearance ≥ 40

          -  Body mass index ≤ 34 Kg/m^2

          -  Not claustrophobic

          -  No other contraindications to MRI (i.e., implanted pacemaker device)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No allergy to gadolinium

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baran Sumer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Simmons Comprehensive Cancer Center a</last_name>
      <phone>866-460-4673; 214-648-7097</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2009</study_first_posted>
  <last_update_submitted>February 26, 2011</last_update_submitted>
  <last_update_submitted_qc>February 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Regulatory Affairs Associate</name_title>
    <organization>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</organization>
  </responsible_party>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>stage III basal cell carcinoma of the lip</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

